The Nanopharmacokinetic Gap

 Despite the tremendous potential of nanomedicine and hundreds of millions poured from funding institutions, it could be acknowledged that little progress has been made towards matching expectations. Thus few years ago, in... [ view full abstract ]

 Despite the tremendous potential of nanomedicine and hundreds of millions poured from funding institutions, it could be acknowledged that little progress has been made towards matching expectations. Thus few years ago, in 2012, Bayer announced that when they tried to replicate results of 67 studies , nearly two-thirds failed, which is in part attributed to poorly described nanomaterials along with the lack of publication of negative results in the scientific community. Also in Nature Nanotechnology there was a call for better described NPs and Harald Krug after analyzing about 10.000 nanotoxicology papers did find serious problems in the state and purity of the employed NPs. More recently, Derek Lowe's commentary on drug discovery and the pharma industry in the Science Magazine Blog, commenting on Analysis of Nanoparticles Delivery to tumours, recognized it again: “Working out that delivery and pharmacokinetics aspects of these things (nanoparticles) was already known to be a challenge, but it’s proven to be even more of one than anybody thought.